Casting a double whammy against Cav3.2: A possible approach to long lasting pain therapy
Chronic pain affects more than 20% of adults but is often refractory to the current arsenal of approved analgesics, thus necessitating the development of new strategies. In an interesting article published in the current issue of Molecular Therapy Nucleic Acids,1 Shin and colleagues describe the analgesic effects of a virally delivered peptide that targets Cav3.2 calcium channel activity.
Authors
- Gerald Werner Zamponi (ORCID: https://orcid.org/0000-0002-0644-9066)
- María A. Gandini (ORCID: https://orcid.org/0000-0003-4399-1679)
Institutions
- University of Calgary (CA)
- Hotchkiss Brain Institute (CA)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.omtn.2026.103167
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research